Ashna Habib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashna Habib has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Tooba Ali
Dow University Of Health Sciences Karachi Pakistan
12 shared publications - Zainab Mbbs Nazir
Dow University of Health Sciences, Karachi, Pakistan
11 shared publications - Ariful Haque
Department of Orthopedic Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China
10 shared publications - Abdullah Nadeem
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Afsheen Khan
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Ajeet Singh
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 31 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72492
Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Background and Aims: Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods: A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results: Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion: Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.
- 31 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72492
Open AccessReproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Background and Aims: Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods: A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results: Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion: Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.
- Open Access
- 29 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 4963-4974
Integrating mental health and cardiovascular wellness: synergistic impacts and the promise of comprehensive care models
This review explores the bidirectional relationship between mental health disorders and cardiovascular disease (CVD), highlighting the potential of integrated healthcare models to improve outcomes. While CVD remains the leading cause of global mortality, traditionally linked to risk factors like hypertension and diabetes, emerging evidence shows that mental health conditions, especially depression and anxiety, significantly increase CVD risk through mechanisms such as chronic stress, inflammation, and neuroendocrine dysregulation. Activation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system exacerbates inflammation, elevates blood pressure, and contributes to cardiovascular risk factors. Moreover, the psychological burden of CVD often worsens mental health, creating a vicious cycle that complicates treatment adherence and patient management. Integrated care models offer a holistic approach to address these interconnected issues, potentially improving clinical outcomes, reducing healthcare costs, and enhancing patient adherence. This review also explores the role of telehealth and digital health interventions in overcoming accessibility barriers, particularly for underserved populations. Finally, policy recommendations emphasize the need for increased funding, professional training in interdisciplinary care, and targeted outreach to ensure equitable access to integrated care. By addressing both CVD and mental health challenges, these models could improve quality of life and reduce the global burden of these intertwined diseases.
- 29 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (8) , 4963-4974
Open AccessIntegrating mental health and cardiovascular wellness: synergistic impacts and the promise of comprehensive care models
This review explores the bidirectional relationship between mental health disorders and cardiovascular disease (CVD), highlighting the potential of integrated healthcare models to improve outcomes. While CVD remains the leading cause of global mortality, traditionally linked to risk factors like hypertension and diabetes, emerging evidence shows that mental health conditions, especially depression and anxiety, significantly increase CVD risk through mechanisms such as chronic stress, inflammation, and neuroendocrine dysregulation. Activation of the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system exacerbates inflammation, elevates blood pressure, and contributes to cardiovascular risk factors. Moreover, the psychological burden of CVD often worsens mental health, creating a vicious cycle that complicates treatment adherence and patient management. Integrated care models offer a holistic approach to address these interconnected issues, potentially improving clinical outcomes, reducing healthcare costs, and enhancing patient adherence. This review also explores the role of telehealth and digital health interventions in overcoming accessibility barriers, particularly for underserved populations. Finally, policy recommendations emphasize the need for increased funding, professional training in interdisciplinary care, and targeted outreach to ensure equitable access to integrated care. By addressing both CVD and mental health challenges, these models could improve quality of life and reduce the global burden of these intertwined diseases.
- Open Access
- 27 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1529-1542
Tethered cord syndrome (TCS) and constipation in children: a multifaceted approach (literature review)
Tethered cord syndrome (TCS) is estimated to affect approximately 25 per 100 000 live births. Despite advancements in medical knowledge and technology, the persistence of this issue is attributed to challenges in early detection and limited awareness, often resulting in undiagnosed cases until adulthood. Constipation serves as a noteworthy symptom in children with TCS, yet it frequently goes unnoticed or is ascribed to other causes, leading to delayed diagnosis and negatively impacting a child’s quality of life. The aim of this manuscript is to explore the relationship between TCS and constipation in children, focusing on the prevalence, clinical manifestations, diagnostic challenges, and existing treatment methods by synthesizing information from relevant literature. Ultimately, the goal is to shed light on the multifaceted aspects of TCS and its connection to constipation, emphasizing the need for a comprehensive, multidisciplinary approach to effectively manage this condition in children. Notably, nerve dysfunction that affects bowel motions is often the cause of constipation in children with TCS. A multimodal strategy that includes pharmaceutical treatments, dietary changes, and novel techniques, like neuromodulation and biofeedback therapy, is required for effective management. Given its safety and tolerance in children, key findings emphasize the effectiveness of osmotic laxatives, especially polyethylene glycol (PEG), as a first-line treatment for chronic constipation. Physical therapies, such as pelvic floor physiotherapy and biofeedback, show promise in enhancing rectal sensation and bowel coordination. Bowel function is typically improved with neurosurgical intervention to reduce spinal cord tethering, although there are risks, including re-tethering. Minimally invasive surgical techniques are promising, but more research is needed. Social and intellectual developments are negatively impacted by psychological effects, which are common and include anxiety and depression associated with chronic gastrointestinal problems. In conclusion, addressing constipation in children with TCS necessitates a multimodal strategy and collaborative efforts across different disciplines for optimal management.
- 27 February 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1529-1542
Open AccessTethered cord syndrome (TCS) and constipation in children: a multifaceted approach (literature review)
Tethered cord syndrome (TCS) is estimated to affect approximately 25 per 100 000 live births. Despite advancements in medical knowledge and technology, the persistence of this issue is attributed to challenges in early detection and limited awareness, often resulting in undiagnosed cases until adulthood. Constipation serves as a noteworthy symptom in children with TCS, yet it frequently goes unnoticed or is ascribed to other causes, leading to delayed diagnosis and negatively impacting a child’s quality of life. The aim of this manuscript is to explore the relationship between TCS and constipation in children, focusing on the prevalence, clinical manifestations, diagnostic challenges, and existing treatment methods by synthesizing information from relevant literature. Ultimately, the goal is to shed light on the multifaceted aspects of TCS and its connection to constipation, emphasizing the need for a comprehensive, multidisciplinary approach to effectively manage this condition in children. Notably, nerve dysfunction that affects bowel motions is often the cause of constipation in children with TCS. A multimodal strategy that includes pharmaceutical treatments, dietary changes, and novel techniques, like neuromodulation and biofeedback therapy, is required for effective management. Given its safety and tolerance in children, key findings emphasize the effectiveness of osmotic laxatives, especially polyethylene glycol (PEG), as a first-line treatment for chronic constipation. Physical therapies, such as pelvic floor physiotherapy and biofeedback, show promise in enhancing rectal sensation and bowel coordination. Bowel function is typically improved with neurosurgical intervention to reduce spinal cord tethering, although there are risks, including re-tethering. Minimally invasive surgical techniques are promising, but more research is needed. Social and intellectual developments are negatively impacted by psychological effects, which are common and include anxiety and depression associated with chronic gastrointestinal problems. In conclusion, addressing constipation in children with TCS necessitates a multimodal strategy and collaborative efforts across different disciplines for optimal management.
- Open Access
- 23 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 7 (5)
The unseen burden: the tangled web of paternal postpartum depression and childhood resilience
Postpartum depression (PPD) is a significant mental health disorder that has received little attention (both clinically and experimentally) and is underdiagnosed. PPD is most associated with mothers after giving birth. However, it may also affect fathers for unknown reasons. Poverty, a family history of depression, and hormonal changes are all risk factors for PPD in fathers. Although not much is known about paternal PPD, research indicates that it is often 8.7% prevalent in the first year, peaking between 3 and 6 months after childbirth (9.2%).
- 23 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 7 (5)
Open AccessThe unseen burden: the tangled web of paternal postpartum depression and childhood resilience
Postpartum depression (PPD) is a significant mental health disorder that has received little attention (both clinically and experimentally) and is underdiagnosed. PPD is most associated with mothers after giving birth. However, it may also affect fathers for unknown reasons. Poverty, a family history of depression, and hormonal changes are all risk factors for PPD in fathers. Although not much is known about paternal PPD, research indicates that it is often 8.7% prevalent in the first year, peaking between 3 and 6 months after childbirth (9.2%).
- Open Access
- 20 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3816-3819
Xylazine in illicit drug mixtures: a growing threat and overlooked danger
An abstract is unavailable. This article is available as a PDF only.
- 20 May 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (7) , 3816-3819
Open AccessXylazine in illicit drug mixtures: a growing threat and overlooked danger
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 17 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3530-3534
Ryzumvi: pioneering advances in countering drug-induced mydriasis
This article discusses the prevalence and impact of pharmacologically-induced mydriasis, a condition where the pupil becomes excessively dilated due to certain drugs. It highlights the challenges faced by medical professionals in dealing with this condition and the limitations of current treatments, like pilocarpine and dapiprazole, which come with systemic side effects and specific contraindications, limiting their regular use. The article introduces Ryzumvi, a novel ophthalmic solution approved by the US FDA, which effectively reverses mydriasis caused by adrenergic agonists and antimuscarinic drugs. The article provides insights into its mechanism of action, clinical efficacy, pharmacokinetics, safety, and tolerance based on extensive clinical trials. It emphasizes its rapid onset of action and effectiveness in restoring pupils to their initial size. It also underlines the potential for expanded applications, including in pediatric patients, solidifying its importance in the field of ophthalmology. Furthermore, Ryzumvi represents a promising advancement in managing pharmacologically-induced mydriasis, offering swift and effective relief while highlighting the importance of adhering to safety precautions and the continuous research and development efforts in ophthalmology to comprehensively address vision-related disorders and enhance patient outcomes.
- 17 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3530-3534
Open AccessRyzumvi: pioneering advances in countering drug-induced mydriasis
This article discusses the prevalence and impact of pharmacologically-induced mydriasis, a condition where the pupil becomes excessively dilated due to certain drugs. It highlights the challenges faced by medical professionals in dealing with this condition and the limitations of current treatments, like pilocarpine and dapiprazole, which come with systemic side effects and specific contraindications, limiting their regular use. The article introduces Ryzumvi, a novel ophthalmic solution approved by the US FDA, which effectively reverses mydriasis caused by adrenergic agonists and antimuscarinic drugs. The article provides insights into its mechanism of action, clinical efficacy, pharmacokinetics, safety, and tolerance based on extensive clinical trials. It emphasizes its rapid onset of action and effectiveness in restoring pupils to their initial size. It also underlines the potential for expanded applications, including in pediatric patients, solidifying its importance in the field of ophthalmology. Furthermore, Ryzumvi represents a promising advancement in managing pharmacologically-induced mydriasis, offering swift and effective relief while highlighting the importance of adhering to safety precautions and the continuous research and development efforts in ophthalmology to comprehensively address vision-related disorders and enhance patient outcomes.
- Open Access
- 4 April 2024
- Published by Elsevier in World Neurosurgery: X
- Vol. 23, 100368
Comparing surgical outcomes: Craniotomy versus decompressive craniectomy in acute subdural hematoma - A systematic review and meta-analysis
- 4 April 2024
- Published by Elsevier in World Neurosurgery: X
- Vol. 23, 100368
Open AccessComparing surgical outcomes: Craniotomy versus decompressive craniectomy in acute subdural hematoma - A systematic review and meta-analysis
- Open Access
- 18 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2591-2597
The level of medical students’ knowledge regarding the prevention of cervical cancer
Background: In Palestine, cervical cancer is the third most common gynaecological cancer, exhibiting higher mortality rates compared to regional counterparts. Late-stage diagnosis and limited awareness contribute to this disparity. This study aims to assess the awareness of Palestinian medical students regarding cervical cancer prevention. Methods: A questionnaire-based survey involving 532 medical students from various Palestinian universities was conducted between October 2023 and December 2023. The survey encompassed closed-ended quantitative and demographic questions distributed through social media. Results: The study was carried out on a group of 532 medical students (66.3% women and 33.6% men), (average age 21.7 years). Most students (77.7%) knew that the main risk factor for cervical cancer was human papillomavirus (HPV) infection. Participants doing the internship had the greatest knowledge, whereas students from the first year had the poorest knowledge about the main risk factors for cancer of the cervix. Only about half, 50.2% of all students, knew that in Palestine, there is no screening program. 84.4% of students correctly indicated that the cervical cancer screening test is a pap smear test. 41.4% of respondents knew that microscopic evaluation of the exfoliated cells from the vaginal part of the cervix is the screening test for cervical cancer which is used. Only about half of the students (45.1%) knew that there were no specific early symptoms of cervical cancer. Conclusions: This study highlights the need for enhanced education, particularly regarding screening program awareness, among Palestinian medical students. Addressing these knowledge gaps is crucial for effective preventive strategies.
- 18 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2591-2597
Open AccessThe level of medical students’ knowledge regarding the prevention of cervical cancer
Background: In Palestine, cervical cancer is the third most common gynaecological cancer, exhibiting higher mortality rates compared to regional counterparts. Late-stage diagnosis and limited awareness contribute to this disparity. This study aims to assess the awareness of Palestinian medical students regarding cervical cancer prevention. Methods: A questionnaire-based survey involving 532 medical students from various Palestinian universities was conducted between October 2023 and December 2023. The survey encompassed closed-ended quantitative and demographic questions distributed through social media. Results: The study was carried out on a group of 532 medical students (66.3% women and 33.6% men), (average age 21.7 years). Most students (77.7%) knew that the main risk factor for cervical cancer was human papillomavirus (HPV) infection. Participants doing the internship had the greatest knowledge, whereas students from the first year had the poorest knowledge about the main risk factors for cancer of the cervix. Only about half, 50.2% of all students, knew that in Palestine, there is no screening program. 84.4% of students correctly indicated that the cervical cancer screening test is a pap smear test. 41.4% of respondents knew that microscopic evaluation of the exfoliated cells from the vaginal part of the cervix is the screening test for cervical cancer which is used. Only about half of the students (45.1%) knew that there were no specific early symptoms of cervical cancer. Conclusions: This study highlights the need for enhanced education, particularly regarding screening program awareness, among Palestinian medical students. Addressing these knowledge gaps is crucial for effective preventive strategies.
- Open Access
- 22 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 62 (2) , 176-177
A call to action: gastric cancer in low- and middle-income nations and the value of screening
- 22 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Open
- Vol. 62 (2) , 176-177
Open AccessA call to action: gastric cancer in low- and middle-income nations and the value of screening
- Open Access
- 16 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2529-2531
Revolutionizing gastric linitis plastica diagnosis: the crucial role of EUS-FNA in a sequential diagnostic approach
An abstract is unavailable. This article is available as a PDF only.
- 16 February 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (5) , 2529-2531
Open AccessRevolutionizing gastric linitis plastica diagnosis: the crucial role of EUS-FNA in a sequential diagnostic approach
An abstract is unavailable. This article is available as a PDF only.